Cargando…

SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency

Detalles Bibliográficos
Autores principales:	Li, Maochen, Lou, Fuxing, Fan, Huahao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035603/ https://www.ncbi.nlm.nih.gov/pubmed/33839737 http://dx.doi.org/10.1038/s41392-021-00592-6

Ejemplares similares

SARS-CoV-2 variant Omicron: currently the most complete “escapee” from neutralization by antibodies and vaccines
por: Li, Maochen, et al.
Publicado: (2022)

SARS-CoV-2 Variants of Concern Delta: a great challenge to prevention and control of COVID-19
por: Li, Maochen, et al.
Publicado: (2021)

Multiple LDLR class A repeats on very‐low‐density lipoprotein receptor promote the cross‐species transmission of Semliki Forest virus
por: Hu, Ruolan, et al.
Publicado: (2023)

The determinants associated with zoonotic potential of influenza A viruses: BTN3A3 evasion mediated by residue mutation in the nucleoprotein
por: Tian, Lili, et al.
Publicado: (2023)

Circular RNA vaccine, a novel mRNA vaccine design strategy for SARS‐CoV‐2 and variants
por: Su, Peng, et al.
Publicado: (2022)

The monkeypox outbreak in 2022: adaptive evolution associated with APOBEC3 may account for
por: Chen, Yangzhen, et al.
Publicado: (2022)

Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
por: Lou, Fuxing, et al.
Publicado: (2021)

Coronavirus Variants—Will New mRNA Vaccines Meet the Challenge?
por: Welsh, Jennifer
Publicado: (2021)

Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum
por: Bates, Timothy A., et al.
Publicado: (2021)

Catch-as-catch-can: mRNA vaccination boosts immune responses to SARS-CoV-2 variants
por: Pawelec, Graham, et al.
Publicado: (2021)

Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
por: Uriu, Keiya, et al.
Publicado: (2021)

Variant constraint by mRNA vaccines
por: Bordon, Yvonne
Publicado: (2021)

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
por: Rössler, Annika, et al.
Publicado: (2022)

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
por: Choi, Angela, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
por: Bates, Timothy A., et al.
Publicado: (2021)

Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity
por: Provine, Nicholas M., et al.
Publicado: (2022)

The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era
por: Fan, Huahao, et al.
Publicado: (2022)

Structural insights into the Omicron spike trimer: tackling the challenges of continuously evolving SARS-CoV-2 variants
por: Ou, Junxian, et al.
Publicado: (2022)

Puzzling mRNA: Alternative splicing fine-tunes specificity and function
por: Häfner, Sophia Julia
Publicado: (2019)

Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum
por: Zhu, Yuqi, et al.
Publicado: (2022)

How will previous infection or current vaccination strategies protect us from future SARS‐CoV‐2 variant infections?
por: Monteiro, Olivia
Publicado: (2022)

mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects
por: Fabricius, Dorit, et al.
Publicado: (2021)

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster
por: Lusvarghi, Sabrina, et al.
Publicado: (2021)

SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies
por: Yang, Yang, et al.
Publicado: (2021)

Highlight: Not Like a Textbook—Nuclear Genes in Blastocystis Use mRNA Polyadenylation for Stop Codons
por: Venton, Danielle
Publicado: (2014)

Efficient disinfection of SARS-CoV-2-like coronavirus, pseudotyped SARS-CoV-2 and other coronaviruses using cold plasma induces spike protein damage
por: Qin, Hongbo, et al.
Publicado: (2022)

SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern
por: Noh, Ji Yun, et al.
Publicado: (2021)

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies
por: Lusvarghi, Sabrina, et al.
Publicado: (2022)

A promiscuous interaction of SARS-CoV-2 with bacterial products
por: Carissimo, Guillaume, et al.
Publicado: (2020)

Virtual Issue on SARS-CoV-2: Evolution of a Pandemic
por: McGrath, Casey
Publicado: (2023)

SARS-CoV-2 Omicron: a new challenge for pandemic and vaccine
por: Zhang, Xiantao, et al.
Publicado: (2022)

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
por: Liu, Chang, et al.
Publicado: (2021)

Autoimmunity and SARS‐CoV‐2 infection: Unraveling the link in neurological disorders
por: Latorre, Daniela
Publicado: (2022)

Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
por: Marcotte, Harold, et al.
Publicado: (2022)

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
por: Gruell, Henning, et al.
Publicado: (2022)

Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
por: Xu, Ailan, et al.
Publicado: (2022)

mRNA vaccine shows promise in autoimmunity
por: Flemming, Alexandra
Publicado: (2021)

Opsonizing antibodies mediated SARS‐CoV‐2 entry into monocytes leads to inflammation
por: Yao, Tong, et al.
Publicado: (2022)

Kidney injury molecule-1: a novel entry factor for SARS-CoV-2
por: Wan, Cheng, et al.
Publicado: (2021)

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies
por: Hu, Jie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i5v8431f71tt0os44bs4r69att